TELA Bio, Inc. — Form 8-K Summary
Reporting date: October 5, 2026 (filed October 6, 2026). This current report covers a Nasdaq listing-status update; it does not report a financial period or financial results.
Key event
TELA Bio reported that Nasdaq notified the company on October 5, 2026 that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). Nasdaq closed the matter. TELA Bio’s common stock remains listed and traded on the Nasdaq Global Market under ticker TELA.
Financial condition and outlook
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or outlook figures. It contains no management commentary on operating performance, risks, or contingencies beyond the listing-status update.
Important facts to verify
- Nasdaq’s notice confirms that the minimum bid price compliance matter is closed.
- The common stock continues trading on the Nasdaq Global Market as TELA.
- This filing does not provide financial results or details of how compliance was regained.